The infusion of ex vivo differentiated myeloid precursors may be able to shorten the period of obligatory neutropenia after high-dose chemotherapy and peripheral blood progenitor cell rescue by providing cells capable of differentiating to mature neutrophils within days of infusion. To test this hypothesis, 21 female patients with metastatic breast cancer underwent progenitor cell mobilization with cyclophosphamide, etoposide and G-CSF. CD34
High-dose chemotherapy with autologous stem cell rescue has significantly improved the outcome for certain patients with malignant disorders by allowing the clinical exploitation of the dose-response relationship. [1] [2] [3] Profound myelosuppression is universal in all patients receiving high-dose chemotherapy, and although infectious complications are infrequently the sole cause of mortality in autologous transplantation, neutropenia does contribute to the morbidity and mortality. The use of the myeloid growth factors 4 and mobilized peripheral blood progenitors 5 have significantly shortened the duration of neutropenia after high-dose chemotherapy. Despite these interventions, there is an obligatory period of pancytopenia that persists even with significant escalations of the progenitor cell dose. 6 Murine models of hematopoiesis have demonstrated serial phases of engraftment after myeloablative chemotherapy, in which committed progenitors provide early, transient hematopoiesis and primitive progenitors establish durable, delayed hematopoiesis. 7 As such, one theory is that the obligatory period of neutropenia after high-dose chemotherapy is the result of an insufficient number of infused myeloid precursors capable of differentiating to mature neutrophils within days of infusion. However, more recent studies have implicated primitive progenitors for early myeloid recovery, 8 finding no role for committed progenitors on engraftment. 9 The ability to generate myeloid precursors and mature neutrophils ex vivo from hematopoietic progenitors has been previously reported with both small scale 10, 11 and clinical scale models. 12 Preclinical studies have also demonstrated that these cells, when maintained in culture, differentiate to fully functional neutrophils. 13 The feasibility of infusing expanded progenitors in the clinical setting has previously been reported, 14, 15 but the clinical impact was less evident in these smaller series. We report here our experience with a larger group of patients with metastatic breast cancer who received ex vivo differentiated myeloid precursors as an adjunct to high-dose chemotherapy and peripheral blood progenitor cell rescue.
Patients and methods

Patient selection
Twenty-one women with chemotherapy-sensitive, metastatic breast cancer were enrolled on an Institutional Review Board approved protocol described below. Signed informed consent was obtained from all participants prior to study entry. No more than one prior regimen for metastatic disease was allowed and all patients demonstrated adequate pulmonary, hepatic, cardiac and renal function. Patients with evidence of bone marrow metastases or active infection including hepatitis B, hepatitis C or human immunodeficiency virus were excluded. A World Health Organization performance status of two or less was required.
Treatment regimen
After placement of an apheresis catheter, peripheral blood progenitors were mobilized with cyclophosphamide (4 g/m ), and G-CSF (10 g/kg/day). Leukapheresis was initiated upon recovery of neutrophils (white blood cell count у1 × 10 9 /l) and platelets (platelet count у20 × 10 9 /l). A total of four to five leukaphereses were performed for each patient. For the first 14 patients (cohort 1), one leukapheresis product was selected and cultured as described below and the remainder were cryopreserved according to a previously published procedure. 16 For the remaining seven patients (cohort 2), two leukapheresis products were pooled, selected and expanded while the remaining products were cryopreserved.
After completion of the harvesting, high-dose cyclophosphamide 1. ) were administered as a continuous infusion over 96 h. Mesna and forced diuresis were administered as prophylaxis for hemorrhagic cystitis. Forty-eight hours after completion of the chemotherapy, the cryopreserved progenitors were rapidly thawed and infused through a central venous catheter. Twenty-four hours after infusion of the cryopreserved progenitors, the differentiated myeloid precursors were infused over 5 to 10 min in the first cohort. For the second cohort of patients, the differentiated myeloid precursors were infused immediately after the cryopreserved product. G -CSF (5 g/kg/day) was started 4 h after infusion of the cryopreserved progenitors and continued until the absolute neutrophil count exceeded 1.0 × 10 9 /l for 2 consecutive days.
Selection and expansion
For cohort one, the designated leukapheresis product underwent CD34 selection and was placed into culture on the day of leukapheresis. For cohort two, the first leukapheresis product was stored overnight at room temperature with autologous plasma and citrate in a gas permeable bag. On the second day, the first product, which had been held overnight, was combined with the second day's product and selected for CD34 + cells as described below. The leukapheresis products were enriched for CD34-positive cells using the Isolex 300 SA immunomagnetic method (Nexel Therapeutics, Irvine, CA, USA). A complete culture medium was prepared consisting of X-VIVO 10 serum-free culture medium (BioWhitaker, Walkersville, MD, USA), 1% human serum albumin (Baxter, Hyland Division, Glendale, CA, USA), 2 mm l-glutamine (Sigma Chemical, St Louis, MO, USA) and 100 ng/ml PIXY321 (Immunex, Seattle, WA, USA). CD34-enriched cells were seeded into the complete culture medium to achieve a final concentration of 1 × 10 5 cells/ml in a prototype PL2417 gas permeable container designed for cell culture (Nexel Therapeutics). The cultures were placed in a high-humidity, 5% CO 2 , 5% O 2 , 37°C incubator. On day 7 of culture, a cell count was performed and the cell concentration was re-adjusted to the initial cell concentration with sub-cultures initiated as needed. On day 12, the cells were pooled, washed and suspended in PlasmaLyte-A (Baxter Healthcare, Deerfield, IL, USA) with 1% human serum albumin using the CS3000 blood cell separator (Baxter).
Product characterization
The total number of nucleated cells in the final product was determined manually using a hemocytometer. Quantitative CD34 analysis was performed by flow cytometry according to a previously published procedure 17 and dual color flow cytometric analysis of CD15 (FITC-conjugated LeuM1; Becton Dickinson, San Jose, CA, USA) and CD11b (PEconjugated Leu15; Becton Dickinson) was performed on the final product. An aliquot of cells from the final product was stained with Wright's stain and examined under light microscopy for analysis of morphology. Cell viability was determined by flow cytometry using propidium iodide and routine microbiological and fungal cultures were obtained. A gram stain was performed on the final product. Clonogenic assays were plated as previously described 18 and scored for CFU-GM (colony-forming unit granulocytemacrophage) and BFU-E (burst-forming unit erythroid).
Immunohistochemistry
An aliquot was obtained from the leukapheresis product, the CD34 + fraction, the CD34 negative fraction, and the final cultured cell product. Cytospin preparations of the cell samples were prepared and the cells were examined for the presence of contaminating tumor cells at BIS Laboratories (Reseda, CA, USA). The cell preparations were stained with two separate cocktails of monoclonal antibodies (MoAbs); Baxter MoAbs 9148, 9187 and 9189 at 5 g/ml, and with BIS MoAbs SB-3 and TSF-2 at 2.5 g/ml as previously reported. 19 Positively stained cells were reviewed morphologically to confirm the presence of malignant cells.
Indium-111 labeled WBC scan
The cultured product from one patient in cohort two was labeled with Indium-111 according to standard clinical practice, and infused through a peripheral venous catheter.
A dual head gamma camera was utilized for imaging to obtain conjugate anterior and posterior images. For 1 h after infusion, stationary images of the lungs, liver and spleen were obtained every 15 s. Subsequent whole body scans were performed at 1, 4, 21 and 52 h post infusion. Quantitative analysis was performed to determine uptake in visceral organs (lung, liver, spleen) and bones (right and left pelvis and cervical vertebrae). Whole blood and urine were sampled at set intervals to track distribution.
Statistics and analysis
The total number of nucleated cells generated in ex vivo culture was assessed. Differentiated myeloid precursors are defined as those ex vivo cultured cells expressing the myeloid marker CD15. Neutrophil recovery was defined as the number of days from reinfusion of the cryopreserved progenitors to achieve an absolute neutrophil count of 0.5 × 10 9 /l. Platelet recovery was defined as the number of days from infusion of the cryopreserved progenitors to a platelet count of 20 × 10 9 /l, independent of transfusions. The 'neutropenic index', used as an indicator of the depth and duration of neutropenia, is a measure of the area under the curve below an ANC of 0.5 × 10 9 /l shown by the shaded area in Figure 1 . The area of each individual trapezoid and triangle was calculated and summed, thus providing an estimate of the depth and duration of neutropenia. When the white blood cell count was less than 0.1 × 10 9 /l, the neutrophil count was considered to be zero despite a manual differential identifying neutrophils and bands. When no differential was available with a white blood cell count greater than 0.1 × 10 9 /l, the average ANC of the surrounding days was utilized. Based on linear regression analysis, the number of ex vivo differentiated myeloid precursors (±95% confidence intervals) needed to totally ablate the period of neutropenia less than 0.5 × 10 9 /l was calculated. 
Results
Patient and product characterization
The characteristics of the 21 patients are detailed in Table 1 . One patient did not mobilize a sufficient number of progenitors to undergo ex vivo culture but cells were harvested for cryopreservation. The results of the CD34 selection with the Isolex 300SA for the remaining 20 patients are detailed in Table 2 . The CD34 selection resulted in a median purity of 98.2% and a median yield of 48%. Cultures were initiated for all of these patients, but the final product for three patients was not suitable for infusion. As such, only 17 patients were infused with the ex vivo differentiated myeloid precursors. The characteristics of the final cellular products are outlined in Table 2 .
There was a median 13-fold expansion of nucleated cells with a range of 5.6 to 1066 × 10 7 nucleated cells infused. Morphologically, the cells were predominantly of myeloid lineage (median 63%). Immunophenotypic analysis demonstrated that a median of 41% of the cells expressed the myeloid antigen CD15. Only a small percentage of cells expressed both CD15 and CD11b (median 18%). There was no expansion of CFU-GM (median 19.3 × 10 6 post culture) and there was a depletion of the total number of CD34 + cells (median 11.3 × 10 7 post culture). No malignant cells were detected in any of the unmanipulated leukapheresis products or CD34 selected products. Both the negative fraction and cultured cells from one patient were found to be contaminated with breast cancer cells (1:3.4 × 10 6 cells and 2:3.5 × 10 6 cells, respectively). 
Clinical results
No serious toxicities were noted with the infusion of the ex vivo differentiated myeloid precursors and no unexpected toxicities were encountered during the hospital course of any of the patients. Serious adverse events which were noted included necrotizing fasciitis originating at the site of a femoral catheter (n = 1), fatal veno-occlusive disease of the liver (n = 1) and self-limited chemotherapy induced lung injury documented on open lung biopsy (n = 1). Ten patients experienced grade 3 mucositis and/or noninfectious diarrhea.
Impact on neutropenia
The median days to neutrophil and platelet recovery were 8 and 10, respectively. There was no significant difference in time to hematopoietic recovery regardless of the day of infusion of the differentiated myeloid precursors. In addition, there was no significant correlation between the number of differentiated myeloid precursors and the days to neutrophil recovery. Subsequently, we explored the relationship between the depth and duration of neutropenia (neutropenic index) and the dose of various cell populations. Linear regression analysis was performed to establish the relationship between the neutropenic index and (1) the total number of CD34 + cells in the cryopreserved leukapheresis products; and (2) the number of ex vivo differentiated (CD15 + ) myeloid precursors. There was an inverse correlation found between the number of differentiated myeloid precursors (CD15 + cells) and the neutropenic index (r = 0.67, P = 0.007). A strong relationship was also noted between the number of infused CD34
+ cells from the cryopreserved leukapheresis products and the neutropenic index (r = 0.82, P Ͻ 0.001). Assuming continuation of the linear relationship between neutropenia and infused cryopreserved progenitors and ex vivo differentiated myeloid precursors, the number of infused cells required to totally ablate the period of neutropenia (ANC Ͻ0.5 × 10 9 /l) was calculated to be 9.6 (±6.2) × 10 7 CD15 + cells/kg.
Indium scanning
Immediately after infusion, uptake was noted in both lungs accounting for more than 90% of the total activity. By 4 h, the lung activity had decreased substantially with activity noted predominantly in the liver and spleen as shown in Figure 2 . Activity was noted in both femoral heads at 1 h and steadily increased over the study period (Figure 2 ). Significant uptake in the cervical vertebrae was not noted. Activity in the peripheral blood was noted immediately after infusion, but dropped to undetectable levels within 10 min. Whole body scans revealed activity in the urinary bladder which was confirmed by urine samples up to 24 h post infusion.
Discussion
Although infectious complications are infrequently the sole cause of mortality in autologous transplantation, neutro- penia and its related complications such as febrile neutropenia contribute considerably to the morbidity and costs of high-dose chemotherapy. As such, the ability to impact on neutropenia should make high-dose chemotherapy safer and more tolerable. Although in our series there was no appreciable impact on the days to neutrophil recovery (defined as the number of days required to achieve an absolute neutrophil count of 0.5 × 10 9 /l), we did discover a trend toward blunting the depth of the neutropenic nadir with escalating doses of differentiated myeloid precursors. However, a similar relationship was observed between blunting of the neutropenic nadir and the dose of cryopreserved CD34 + progenitors in the cryopreserved products. Hence, interpretation of the clinical impact of the myeloid progenitors in this trial is not feasible.
Assuming continuation of the linear relationship between myeloid precursors and neutropenia, a total of 9.6 (±6) × 10 7 myeloid precursors (CD15 + cells)/kg would be required to totally ablate the period of neutropenia. A computer model has demonstrated that myeloid precursors could abolish the period of neutropenia when the total number of infused cells exceeded 5.7 × 10 8 /kg. 20 The number which we extrapolated from our data approaches the number identified by this computer-generated model. The blunting of the nadir with cultured progenitors has been previously described in murine models. 21 The thrombocytopenic nadir in mice receiving cultured progenitors was blunted when compared to controls. As for neutrophil recovery, the duration of neutropenia was shortened in addition to blunting of the nadir.
The first report of ex vivo cultured progenitor cells after high-dose chemotherapy demonstrated modest increases in the peripheral white blood cell count which were only short-lived. 14 The number of nucleated cells infused was considerably less than the required estimate extrapolated from this series or from the computer-generated model. In other clinical trials of ex vivo cultured precursors, less committed progenitors were expanded and infused 22 and there was no appreciable impact on the duration of the neutropenic period.
The absence of a clear clinical benefit from this trial may be related to one of several reasons. The number of infused progenitors in this trial may have been insufficient to have a clear clinical benefit. Because cytokine combination and culture conditions may significantly impact on the overall expansion, 23 this could be overcome with the development of a new culture system. This system was utilized because of its ability to reliably generate myeloid precursors. 12 Conversely, as suggested by others, committed myeloid progenitors may have no appreciable impact on engraftment regardless of the cell dose. 8, 9 The circulation and distribution of myeloid precursors after infusion is important for the development of effective clinical protocols. Although there were certain notable differences, our study demonstrated that ex vivo differentiated myeloid precursors follow a pattern typical of Indium-111 labeled granulocytes. 24 Bone marrow has been reported as a site of localization of radio-labeled granulocytes, which in delayed images may be related to the destruction of granulocytes. Bone marrow localization is decreased in patients receiving chemotherapy, 25 making this finding of interest in light of the profound aplasia from the high-dose chemotherapy. The peripheral blood samples demonstrated the rapid and complete resolution of radioactivity confirming previous studies which have demonstrated no increase in circulating granulocytes after infusion of marrow autografts. 26 The low incidence of tumor cell contamination of the peripheral blood product is consistent with the low tumor burden of these patients. 27 As such, it is difficult to draw any firm conclusion regarding the impact of this culture system on tumor cell contamination.
The impact of ex vivo cultured myeloid progenitors remains ambiguous and clinical trials with controlled doses of CD34 + cells and escalating doses of ex vivo differentiated myeloid precursors are required to delineate this further. Although ex vivo differentiated myeloid precursors may substantially reduce the period of neutropenia after high-dose chemotherapy and peripheral blood progenitor cell rescue, it remains unclear whether a clinically significant impact will be realized in the setting of autologous transplantation. There are perhaps other settings in which this technology may be of more recognizable benefit, such as cord blood stem cell transplants. Due to the limited number of progenitors in this setting, cord blood transplants in larger children and adults have resulted in prolonged periods of neutropenia. 28 The use of ex vivo differentiated myeloid precursors in this and other settings holds promise in making transplantation safer and more cost effective.
